MIN-101治疗精神分裂症阴性症状的12周随机双盲安慰剂对照试验
该12周随机双盲安慰剂对照试验纳入244例症状稳定至少3个月且PANSS阴性分量表≥20分的精神分裂症患者,停药至少5天后随机接受安慰剂或MIN-101 32mg/日或64mg/日。结果显示MIN-101两个剂量组PANSS阴性因子分均显著低于安慰剂组(效应量d=0.45和d=0.57),且耐受性良好。
要点
- MIN-101 32mg/日和64mg/日改善阴性症状优于安慰剂,效应量分别为d=0.45和d=0.57
- MIN-101对PANSS阳性症状评分与安慰剂无显著差异
- 生命体征、常规实验室、体重、代谢指标及AIMS评分未见临床显著变化
核心结论
- MIN-101在稳定期精神分裂症患者中显著改善阴性症状且耐受性良好。
研究设计与样本
- 12周随机双盲安慰剂对照试验,纳入244例症状稳定至少3个月且PANSS阴性分量表≥20分的患者。
- 停药至少5天后随机分配至安慰剂、MIN-101 32mg/日或64mg/日组。
主要发现
- MIN-101 32mg/日和64mg/日组PANSS阴性因子分显著低于安慰剂组,效应量分别为d=0.45和d=0.57。
- PANSS阴性症状、总分、激活因子分、CGI严重度条目及简明阴性症状量表等次要指标结果与主要结果一致。
- PANSS阳性量表分在MIN-101与安慰剂组间无统计学显著差异。
- 生命体征、常规实验室值、体重、代谢指标及异常不自主运动量表评分未见临床显著变化。
关键数值与推荐
- 主要结局为PANSS阴性因子分(五边形结构模型)。
- 次要结局包括PANSS总分、CGI、简明阴性症状量表、精神分裂症认知简明评估及卡尔加里抑郁量表。
临床怎么用
- MIN-101可能作为改善精神分裂症阴性症状的候选药物,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors assessed the efficacy, safety, and tolerability of MIN-101, a compound with affinities for sigma-2 and 5-HT2A receptors and no direct dopamine affinities, in comparison with placebo in treating negative symptoms in stabilized patients with schizophrenia. METHOD: The trial enrolled 244 patients who had been symptomatically stable for at least 3 months and had scores of at least 20 on the negative subscale of the Positive and Negative Syndrome Scale (PANSS). After at least 5 days' withdrawal from all antipsychotic medication, patients were randomly assigned to receive placebo or 32 mg/day or 64 mg/day of MIN-101 for 12 weeks. The primary outcome measure was the PANSS negative factor score (pentagonal structure model). Secondary outcome measures were PANSS total score and scores on the Clinical Global Impressions Scale (CGI), the Brief Negative Symptom Scale, the Brief Assessment of Cognition in Schizophrenia, and the Calgary Depression Scale for Schizophrenia. RESULTS: A statistically significant difference in PANSS negative factor score was observed, with lower scores for the MIN-101 32 mg/day and 64 mg/day groups compared with the placebo group (effect sizes, d=0.45 and d=0.57, respectively). Supporting these findings were similar effects on several of the secondary outcome measures, such as the PANSS negative symptom, total, and activation factor scores, the CGI severity item, and the Brief Negative Symptom Scale. There were no statistically significant differences in PANSS positive scale score between the MIN-101 and placebo groups. No clinically significant changes were observed in vital signs, routine laboratory values, weight, metabolic indices, and Abnormal Involuntary Movement Scale score. CONCLUSIONS: MIN-101 demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients.
引用
- Davidson M, Saoud J, Staner C, et al. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017. PMID: 28750582. doi:10.1176/appi.ajp.2017.17010122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。